PC
ITCI

PointState Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PointState Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-475,000
Closed -$8.39M – 192
2018
Q2 		$8.39M Sell
475,000
-1,393,600
-75% -$28.3M 0.1% 108
2018
Q1 		$39.3M Buy
+1,868,600
New +$36.4M 0.43% 63

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PointState Capital's ITCI Position: Q3 2018 in Review

PointState Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2018, closing a stake of 475,000 shares — an estimated $8.39M sold.

PointState Capital first reported a position in ITCI in Q1 2018 and held it in 2 quarters. The position peaked at $39.3M in Q1 2018. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2018.

  • PointState Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 475,000 Intra-Cellular Therapies Inc. shares in Q3 2018, an estimated $8.39M.
  • PointState Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 2 quarters.
  • PointState Capital's Intra-Cellular Therapies Inc. position peaked at $39.3M in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.